Aldara News and Research

RSS
Aldara (imiquimod) is a synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. Check for active clinical trials or closed clinical trials using this agent.
Meda reaches agreement with Valeant to terminate joint ventures

Meda reaches agreement with Valeant to terminate joint ventures

Scientists decode unknown mechanism of imiquimod in tumour defense

Scientists decode unknown mechanism of imiquimod in tumour defense

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

FDA approves Taro's Imiquimod Cream ANDA

FDA approves Taro's Imiquimod Cream ANDA

Graceway receives FDA approval for Zyclara Cream to treat genital warts

Graceway receives FDA approval for Zyclara Cream to treat genital warts

Topical cream used to treat skin diseases activates two distinct neuronal signaling pathways

Topical cream used to treat skin diseases activates two distinct neuronal signaling pathways

NIAID scientists confirm antiviral activity of two lead compounds against HPV

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Perrigo first quarter revenue increases 21% to record $641 million

Perrigo first quarter revenue increases 21% to record $641 million

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Zyclara 3.75% more effective than cryotherapy alone in treatment of Actinic Keratoses: Study

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Watson Pharmaceuticals first-quarter net revenue up 28% to $856.5M

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

Meda AB's net sales for first-quarter 2010 decrease 14% to SEK 2,943M

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK

E. Fougera receives first generic approval for Imiquimod Cream 5%

E. Fougera receives first generic approval for Imiquimod Cream 5%

Meda publishes 2009 year-end report

Meda publishes 2009 year-end report